Member Directory
Primary tabs
Chair: Charles Flexner
Objectives:
- Create the scientific and programmatic agenda of LEAP to ensure a balanced and objective resource for those engaged in developing LA/ER agents for treatment and prevention of HIV, TB, and Hepatitis B & C.
- Bring a broad representation including academic experts in LA/ER therapeutic drug development, community representatives, and non-governmental organizations (NGO’s) with an interest in supporting this field.
- Serve as an honest broker to bridge gaps between academia, regulatory agencies, the pharmaceutical industry, and the community.
Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Receives consulting fees from Gilead Sciences, Merck, Janssen, ViiV Healthcare. Has an ownership interest in Navigen LLC, and receives grant funding from Gilead Sciences. |
![]() Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. Conflict of Interest: Receives royalties from emocha Health, miDiagnostics, consulting fees from Merck, Hologic, and grant funding from emocha Health. |
![]() Polly Clayden has been working as an advocate and activist for over 12 years and co-founded i-Base in April 2000 Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Dr. Paul L. Domanico holds a PhD in Chemistry and a Bachelor of Science degree in Pre-Medicine from Penn State University. He received his post-doctoral training in Molecular Biophysics at E.I. du Pont de Nemours and Co. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. Conflict of Interest: No disclosures. |
![]() Jeffrey M. Jacobson, MD is Professor of Medicine at Case Western Reserve University and Principal Investigator of the Case AIDS Clinical Trials Unit. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. Conflict of Interest: Receives consulting fees from AbbVie, Atea, Decoy, Gilead, GlaxoSmithKline, Janssen, Merck, Moderna, Novartis, Pfizer, Shinogi, ViiV, ViroStatics, and research funding from Gilead, Merck, Viiv. |
![]() Imelda Mahaka is the Executive Director for Pangaea Zimbabwe AIDS Trust (PZAT). She provides strategic direction, overall oversight, coordination, and support for the implementation of PZAT programs. Conflict of Interest: |
![]() Ms. McKenzie-White is Managing Director and Senior Program Officer at the Center for Clinical Global Health Education. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. Conflict of Interest: Dr. Mirochnick has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck, ViiV, Gilead, AstraZeneca. |
![]() Adeniyi Olagunju is a Tenure Track Fellow in the Department of Pharmacology and Therapeutics at the University of Liverpool. He is a member of the Centre of Excellence for Long-acting Therapeutics (CELT) where he leads the Perinatal Pharmacology Group. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare |
![]() Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. Conflict of Interest: None disclosed. |
![]() Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA. Conflict of Interest: Receives research grants to her institution from ViiV Healthcare. |
![]() David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: Has no real or apparent conflicts of interest to report. |